Institution
Nereus Pharmaceuticals
About: Nereus Pharmaceuticals is a based out in . It is known for research contribution in the topics: Proteasome inhibitor & Salinosporamide A. The organization has 96 authors who have published 121 publications receiving 7375 citations.
Papers
More filters
TL;DR: It is shown that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and Bortezomib therapies, which provides the rationale for clinical protocols evaluating NPI -0052, alone and together with Bortzomib, to improve patient outcome in MM.
671 citations
TL;DR: From a global perspective the marine pharmaceutical pipeline remains very active, and now has sufficient momentum to deliver several additional compounds to the marketplace in the near future; this review provides a current view of the pipeline.
577 citations
TL;DR: This review discusses briefly the present understanding of TNF-α-mediated biology and the current injectable therapies in clinical use, and focuses on some of the new therapeutic approaches with oral, small-molecule inhibitors.
Abstract: The functioning of the immune system is finely balanced by the activities of pro-inflammatory and anti-inflammatory mediators or cytokines. Unregulated activities of these mediators can lead to the development of serious inflammatory diseases. In particular, enhanced tumour-necrosis factor-α (TNF-α) synthesis is associated with the development of rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Inhibiting TNF-α activities in these diseases has been remarkably successful. However, the current injectable protein therapies have associated risks and limitations. An oral, small molecule that regulates TNF-α biology could either replace the injectables or provide better disease control when used alone or in conjunction with existing therapies. In this review, we discuss briefly the present understanding of TNF-α-mediated biology and the current injectable therapies in clinical use, and focus on some of the new therapeutic approaches with oral, small-molecule inhibitors.
536 citations
TL;DR: Marine actinomycetes are a prolific but underexploited source for the discovery of novel secondary metabolites and have the potential to be developed as therapeutic agents.
523 citations
TL;DR: Recently, the development of new technologies has revolutionized the screening of natural products and offers a unique opportunity to re-establish natural products as a major source for drug discovery.
519 citations
Authors
Showing all 96 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Dharminder Chauhan | 101 | 343 | 36111 |
| Michael A. Palladino | 57 | 176 | 18857 |
| David White | 55 | 520 | 11856 |
| Emmanuel A. Theodorakis | 45 | 205 | 7384 |
| Yoshio Hayashi | 27 | 154 | 2759 |
| Barbara C. M. Potts | 26 | 42 | 3175 |
| Benjamin Nicholson | 23 | 42 | 3366 |
| Kin Sing Lam | 22 | 64 | 1359 |
| Kin S. Lam | 19 | 32 | 2718 |
| Saskia T. C. Neuteboom | 18 | 44 | 2256 |
| Ginger Tsueng | 16 | 35 | 1228 |
| Jianlin Xu | 15 | 36 | 776 |
| Matthew A. Spear | 14 | 35 | 849 |
| Venkat R. Macherla | 13 | 22 | 2234 |
| G. K. Lloyd | 12 | 19 | 872 |